TriHIBit – DiphtheriaTetanus Toxoids Pertussis Vaccine Haemophilus influenzae type b Conjugate Vaccine

DiphtheriaTetanus Toxoids Pertussis Vaccine Haemophilus influenzae type b Conjugate Vaccine Brand Names- ActHIB With DTP | TriHIBit

What is DiphtheriaTetanus Toxoids Pertussis Vaccine Haemophilus influenzae type b Conjugate Vaccine

Diphtheria toxoids tetanus toxoids pertussis vaccine Haemophilus influenzae type b conjugate vaccine (TriHIBit) is a combination vaccine created when Tripedia (diptheria toxoids; tetanus toxoids; acellular pertussis vaccine adsorbed [DtaP]), which is a liquid formulation, is used to reconstitute ActiHIB (Haemophilus influenzae type b conjugate vaccine [Hib]).

The combination product is indicated for the active immunization of children 15—18 months of age who have completed primary immunization with DTP and Hib vaccines.

Clinical trials have indicated that when TriHIBit is administered to children less than 15 months of age, the immune response to the Hib portion of the vaccine is not as great as that which occurs when ActHIb is administered alone; therefore TriHIBit should not be used in children less than 15 months of age for primary immunization.

TriHIBit was approved by the FDA in 1996.

Indications

  1. diphtheria prophylaxis
  2. Haemophilus influenzae type b prophylaxis
  3. pertussis prophylaxis
  4. tetanus prophylaxis

Side Effects

  1. aluminum toxicity
  2. anaphylactic shock
  3. anaphylactoid reactions
  4. angioedema
  5. anorexia
  6. apnea
  7. arthralgia
  8. bronchospasm
  9. chills
  10. cyanosis
  11. diarrhea
  12. drowsiness
  13. dyspnea
  14. encephalopathy
  15. erythema
  16. fever
  17. Guillain-Barre syndrome
  18. headache
  19. hemolytic anemia
  20. hypoesthesia
  21. hypotension
  22. hypotonia
  23. inconsolable crying
  24. increased intracranial pressure
  25. injection site reaction
  26. irritability
  27. lethargy
  28. lymphadenopathy
  29. maculopapular rash
  30. muscle paralysis
  31. myelitis
  32. nausea
  33. neuritis
  34. paresthesias
  35. peripheral neuropathy
  36. pruritus
  37. purpura
  38. rash
  39. renal failure (unspecified)
  40. seizures
  41. syncope
  42. thrombotic thrombocytopenic purpura (TTP)
  43. urticaria
  44. vomiting
  45. weakness

Monitoring Parameters

  • laboratory monitoring not necessary

Contraindications

  • anticoagulant therapy
  • bleeding
  • breast-feeding
  • children
  • coagulopathy
  • coma
  • encephalopathy
  • fever
  • Guillain-Barre syndrome
  • hemophilia
  • human immunodeficiency virus (HIV) infection
  • immunosuppression
  • infants
  • infection
  • intraarterial administration
  • intravenous administration
  • latex hypersensitivity
  • leukemia
  • lymphoma
  • neonates
  • neurological disease
  • pregnancy
  • seizure disorder
  • seizures
  • severe combined immunodeficiency (SCID)
  • shock
  • subcutaneous administration
  • thimerosal hypersensitivity
  • thrombocytopenia
  • vitamin K deficiency

Interactions

  • Ocrelizumab
  • Siponimod
15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856